CRBP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Corbus Pharmaceuticals Holdings Inc (CRBP) is not a strong buy for a beginner, long-term investor at this time. The technical indicators, options data, and financial performance do not present a compelling case for immediate investment. While analysts see potential upside, the stock's current technical weakness and lack of significant positive catalysts suggest waiting for further developments or a clearer entry point.
The technical indicators show bearish trends with the MACD histogram below 0, RSI in the neutral zone at 43.084, and moving averages in a bearish alignment (SMA_200 > SMA_20 > SMA_5). Key support is at 7.407, and resistance is at 8.538. The stock is trading below its pivot point of 7.972, indicating weakness.
Analysts from RBC Capital see potential upside with a price target of $53, citing the company's undervaluation and promising assets in cancer and obesity treatment. The firm's net income and EPS have shown significant YoY improvement, albeit still negative.
The stock has a 30% chance of declining by -6.35% in the next day and -6.23% in the next week, based on historical candlestick patterns. Technical indicators are bearish, and there are no recent news or significant trading trends from insiders or hedge funds. Additionally, the company's financials show no revenue growth and a negative net income.
In Q3 2025, revenue remained at $0 with no YoY growth. Net income improved by 69.35% YoY but remains negative at -$23.34M. EPS improved by 65.22% YoY to -1.9. Gross margin remains at 0%. Overall, financial performance is weak but shows some improvement in losses.
RBC Capital has an Outperform rating with a price target of $53, citing undervaluation and potential in its cancer and obesity assets. However, robust de-risking data is still a few quarters away, and the stock remains speculative at this stage.
